App-Quantinova.ai

Characterization of the exposure-response relationship leading to recommendations for dosing optimization in a new drug application review.

Jun Yang - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Hand foot syndrome

Cabozantinib

Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).

Andrea Borghese Apolo - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Bladder Cancer

Cabozantinib

A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma.

Andrea Borghese Apolo - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cabozantinib

An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort.

Howard I. Scher - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

Cabozantinib

Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib.

Josef J. Fox - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Qualitative assessment of the brief pain inventory (BPI) pain at its worst in the last 24 hours item to support assessment of pain as a clinical trial endpoint in metastatic castrate resistant prostate cancer (mCRPC) per FDA labeling standards.

Antonia V. Bennett - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Computer-aided bone scan lesion area quantitation: Inter-reader measurement variability.

Gregory H. Chu - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Cabozantinib

A phase II trial of cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219).

Petros Grivas - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Cabozantinib

A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).

Fatima H. Karzai - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study.

Steven I. Sherman - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thyroid Cancer

Cabozantinib

Long-term disease control of ?2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study.

Ezra E.W. Cohen - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Medullary thyroid carcinoma

Cabozantinib

Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials.

Alexander Edward Dela Cruz Drilon - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cabozantinib

Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).

Adil Daud - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Uveal melanoma

Cabozantinib

Application of MET pharmacodynamic assays to compare effectiveness of five MET inhibitors to engage target in tumor tissue.

Apurva K. Srivastava - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Cabozantinib

Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT).

Eric P. Winer - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cabozantinib

Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT).

Chris Verslype - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).

Toni K. Choueiri - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Cabozantinib

Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).

Matthew Raymond Smith - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

Cabozantinib

Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases.

Richard J. Lee - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.

Patrick Schoffski - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Medullary thyroid carcinoma

Cabozantinib

Filters

366 Abstracts